Seattle, Washington – Nohla Therapeutics Inc. (Nohla), a biotechnology company pioneering the field of universal donor cellular therapies for treating patients with life threatening hematological disorders and cancers, today announced the initial closing of a $43.5M Series A financing round. [Read more…]
Using HLA “Super Donors”, ORIG3N’s Crowdsourced Cell Repository Contains Donor Matches for 90% of U.S.
ORIG3N announced it has identified “super donor” matches for 90 percent of the U.S. population. The discovery will accelerate how quickly and successfully we match people for transplants, as tissue can be generated from these cells. ORIG3N was able to achieve this milestone approximately 5x faster than its Japanese counter parts because it has built the world’s largest crowdsourced cell repository called LifeCapsule.
HLA is short for “human leukocyte antigen.” It is a gene complex encoding the cell-surface proteins that control regulation of the human immune system. More simply, it is a protein found on most cells of your body that determines how your body recognizes what is you versus other.
HLA “super donors” are people with tissues that are immunologically compatible with a large percentage of the human population. They are very rare in the population, making them difficult to identify.
The signficanceof this announcement by ORIG3N is that for the first time in history, a complete set of matched samples has been identified and can be industrially produced. Utilizing induced pluripotent stem cell (iPSC) technology, any of the 200+ tissues that compose the human body can now be created.
Importantly, these tissues would be an exact match to the individuals requiring them, even though they were derived from another person (an allogenic transplant).
According to ORIG3N, in the near future, this approach may allow people to rapidly get an exact match for a transplant, instead of waiting for months. Instead, tissues could be “pre-produced.”
For more information, visit www.orig3n.com.
Cord Blood Market Trends, by Region and Sub-Segment
The cord blood market is a complex international industry, composed of public, private, and hybrid cord blood banks.
These market participants store a range of varied products, including cord blood, cord tissue, and sometimes, related perinatal tissues and stem cell types. Rates of cord blood utilization for clinical use vary substantially as well.
Therefore, our approach to analyzing cord blood market trends is to look at it geographically, as well as by sub-segment according to blood units banked, tissue units banked, and clinical units transplanted.
A high level assessment of cord blood market growth is that North American is flat, North Asia and Southeast Asia (SEA) are growing by double digits, and Europe is declining.
We summarize these cord blood industry trends as follows:
To learn more, read our recent interview with Kenneth Harris of CuraSense Advisors, in which we discuss growth rates and trends within the global cord blood banking industry.
Okyanos – Adipose-Derived Stem Cell Treatments with CEO Matt Feshbach
Founded in 2011, Okyanos (pronounced “Oh – key – AH – nos”) is an innovative stem cell therapy provider that specializes in treating patients with congestive heart failure (CHF) and other chronic conditions. The literary name Okyanos, the Greek God of the river Okyanos, symbolizes the restoration of blood flow. Okyanos Cell Therapy delivers a mixed population of fat (adipose) derived stem and regenerative cells (ADRCs) using internationally-approved technology to patients with chronic, degenerative conditions. Okyanos is fully licensed under the Bahamas Stem Cell Therapy and Research Act and adheres to U.S. surgical center standards. [Read more…]
Cynata’s “Major Breakthrough” in MSC Manufacturing – Unlimited Quantities, Uniform Batches, Single Donor, & Low Cost
For years, it has been clear that mesenchymal stem cells (MSCs) are a leading type of stem cell being investigated for therapeutic applications, as they have the potential to treat a wide range of acute and degenerative diseases. In addition to secreting factors that can stimulate tissue repair, MSCs can substantially alter their microenvironment, exerting effects that are both anti-inflammatory and anti-fibrotic.
MSCs are also advantageous over other stem cells types, because they avoid the ethical issues that surround embryonic stem cell research and appear to be immuno-privileged. Importantly, MSCs also well-suited for use in the exponential growth area of 3D printing, because of their unusual capacity to form structural tissues. [Read more…]
- « Previous Page
- 1
- …
- 228
- 229
- 230
- 231
- 232
- …
- 308
- Next Page »